2. Search Result
Search Result
Results for "

<i>Pasteurella piscicida sp.</i> 639

" in MedChemExpress (MCE) Product Catalog:

3349

Inhibitors & Agonists

9

Screening Libraries

150

Fluorescent Dye

104

Biochemical Assay Reagents

298

Peptides

57

MCE Kits

66

Inhibitory Antibodies

707

Natural
Products

457

Recombinant Proteins

117

Isotope-Labeled Compounds

319

Antibodies

43

Click Chemistry

162

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100530C
    Sp-cAMPS sodium salt

    		PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS sodium salt
  • HY-E70056
    α2,3-Sialyltransferase, Pasteurella multocida (P-1059)

    PmST1(M144D)

    		 Sialyltransferase Infection
    α2,3-Sialyltransferase, Pasteurella multocida (P-1059) (PmST1(M144D)), a sialyltransferase, can be isolated from Pasteurella multocida. alpha-2,3-Sialyltransferase (PmST1) can be converted into regioselective α2-6-sialyltransferase by saturation mutagenesis and regioselective screening .
    α2,3-Sialyltransferase, Pasteurella multocida (P-1059)
  • HY-N12322
    Dihydrotetrodecamycin

    		Antibiotic Bacterial Infection
    Dihydrotetrodecamycin is an antibiotic that can be isolated from the fermentation broth of Streptomyces nashvillensis MJ885-mF8. Dihydrotetrodecamycin has MIC values of 50 mg/mL against both Pasteurella piscicida sp. 639 and P. piscicida sp. 6356 .
    Dihydrotetrodecamycin
  • HY-100530B
    Sp-cAMPS

    		PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS
  • HY-110005
    Sp-cAMPS triethylamine

    		PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS triethylamine
  • HY-137629
    Sp-8-pCPT-PET-cGMPS

    		PKG Cardiovascular Disease
    Sp-8-pCPT-PET-cGMPS is an activator for PKG-I. Sp-8-pCPT-PET-cGMPS can be used for research of NO/NOS/sGC/PKG-I signaling pathway in cardiac differentiation .
    Sp-8-pCPT-PET-cGMPS
  • HY-N14238
    Epoxyquinomicin B

    		Antibiotic Bacterial Infection Inflammation/Immunology Cancer
    Epoxyquinomicin B is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin B exhibits inhibitory activity against Micrococcus luteus, Bacillus subtilis, Pasteurella piscicida and Staphylococcus aureus with a MIC of 6.25-12.5 µg/mL. Epoxyquinomicin B exhibits cytotoxicity in cancer cell L1210 with IC50 of 16.3 µg/mL. Epoxyquinomicin B exhibits anti-inflammatory effects against collagen-induced arthritis .
    Epoxyquinomicin B
  • HY-N14237
    Epoxyquinomicin A

    		Antibiotic Bacterial Infection Inflammation/Immunology Cancer
    Epoxyquinomicin A is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin A exhibits inhibitory activity against Micrococcus luteus, Bacillus subtilis, Pasteurella piscicida and Staphylococcus aureus with a MIC of 3-12.5 µg/mL. Epoxyquinomicin A exhibits cytotoxicity in cancer cell L1210, B16 and S180 with IC50 of 2-8 µg/mL. Epoxyquinomicin A exhibits anti-inflammatory effects against collagen-induced arthritis .
    Epoxyquinomicin A
  • HY-137108
    Sp-8-pCPT-cGMPS

    		PKA PKG Neurological Disease
    Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of protein kinase G (types I α, I β, and II) and protein kinase A type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission .
    Sp-8-pCPT-cGMPS
  • HY-137633
    Sp-8-Br-PET-cGMPS

    		PKG Neurological Disease
    Sp-8-Br-PET-cGMPS is a membrane-permeable PKG agonist and a membrane-permeable inhibitor of retinal-type cGMP-gated ion channels, as well as an activator of cGMP-dependent protein kinases I α and I β. Sp-8-Br-PET-cGMPS is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases, has no metabolic side effects, and is more lipophilic and permeable than Sp-8-pCPT-cGMPS. Sp-8-Br-PET-cGMPS can be used to study the role of cGMP signaling pathways in the nervous system .
    Sp-8-Br-PET-cGMPS
  • HY-137628
    Sp-8-PIP cAMP

    		PKA Cancer
    Sp-8-PIP cAMP sodium is a non-corresponding isomer of 8-Piperidino-cAMP. 8-Piperidino-cAMP binds with high affinity to site A of the regulatory subunit of cAMP-dependent protein kinase type I (AI). Sp-8-PIP cAMP sodium can be used as an antagonist of cAMP-induced activation .
    Sp-8-PIP cAMP
  • HY-120994B
    Sp-8-CPT-cAMPS

    		PKA Neurological Disease Inflammation/Immunology
    Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .
    Sp-8-CPT-cAMPS
  • HY-P10951
    (R)-Zadavotide guraxetan

    (R)-PSMA I&T; (R)-PNT-2002

    		 PSMA Cancer
    Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
    (R)-Zadavotide guraxetan
  • HY-P2724A
    Purine nucleoside phosphorylase, Bacillus sp.

    PNP, Bacillus sp.

    		 Endogenous Metabolite Metabolic Disease
    Purine nucleoside phosphorylase, Bacillus sp. is a key enzyme in purine metabolism, involved in the purine salvage pathway. A deficiency in Purine nucleoside phosphorylase, Bacillus sp. can lead to impaired T-cell function. In the presence of inorganic phosphate as a second substrate, Purine nucleoside phosphorylase, Bacillus sp. catalyzes the cleavage of the glycosidic bond of ribonucleosides and deoxyribonucleosides, producing purine bases and ribose (or deoxyribose)-1-phosphate. Purine nucleoside phosphorylase, Bacillus sp. can be used for the determination of inorganic phosphate .
    Purine nucleoside phosphorylase, Bacillus sp.
  • HY-110182
    SP-141
    2 Publications Verification

    		 MDM-2/p53 Cancer
    SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells .
    SP-141
  • HY-N8355
    Beauveriolide I

    		Endogenous Metabolite Infection
    Beauveriolide I is the metabolite of Entomopathogenic Fungi Beauveria sp.. Beauveriolide I (1) exhibits moderate insecticidal activities against Spodoptera litura and Callosobruchus chinensis .
    Beauveriolide I
  • HY-P2917A
    Glycerol kinase, Cellulomonas sp.

    GyK, Cellulomonas sp.

    		 Endogenous Metabolite Others
    Glycerol kinase, Cellulomonas sp. (EC 2.7.1.30) is a bacterial sugar kinase, is often used in biochemical studies. Glycerol kinase, Cellulomonas sp. catalyzes the first step of glycerol metabolism by transforming the triol into glycerol-3-P (G3P). Glycerol kinase, Cellulomonas sp. is crucial for regulating channel/facilitator-independent uptake of glycerol into the cell .
    Glycerol kinase, Cellulomonas sp.
  • HY-135137
    Leptosin I

    		Others Cancer
    Leptosin I is found in the strain of Leptosphaeria sp. OUPS-4. Leptosin I inhibits Leukemia lymphocyte P388 in culture with an ED50 of 1.13 μg/mL .
    Leptosin I
  • HY-P2776B
    Hexokinase, Bacillus sp.

    		Endogenous Metabolite Others
    Hexokinase, Bacillus sp. catalyzes the phosphorylation of glucose, and is involved in glycolysis. Hexokinase, Bacillus sp. participates is also related to energy production, protection of mitochondrial integrity, and cell survival .
    Hexokinase, Bacillus sp.
  • HY-144646
    SP-471

    		Flavivirus Dengue Virus Virus Protease Infection
    SP-471 is a potent dengue virus (DENV) protease inhibitor with IC50 value of 18 μM. SP-471 inhibits both intermolecular and intramolecular protease processes of DENV .
    SP-471
  • HY-P3258
    SP-10

    		Cholinesterase (ChE) Infection
    SP-10 is a small peptide derived from S protein with an IC50 value of 1.88 nM for blocks the interaction between S protein and ACE2. SP-10 can be used for SARS-CoV research .
    SP-10
  • HY-155176
    SP-2-225

    		HDAC Cancer
    SP-2-225 is a selective HDAC6 inhibitor. SP-2-225 enhance the production of cancer-associated antigens and macrophage antigen cross-presentation to T cells. SP-2-225 reduces the tumor volume in a syngeneic SM1 melanoma model .
    SP-2-225
  • HY-147986
    hCA I-IN-2

    		Carbonic Anhydrase Cancer
    hCA I-IN-2 (Compound 6d) is a selective human carbonic anhydrase I (hCA I) inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
    hCA I-IN-2
  • HY-147985
    hCA I-IN-1

    		Carbonic Anhydrase Cancer
    hCA I-IN-1 (Compound 6q) is a human carbonic anhydrase I (hCA I) inhibitor with Ki values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
    hCA I-IN-1
  • HY-110177
    SP-100030
    1 Publications Verification

    		 NF-κB Inflammation/Immunology
    SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC50s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA) .
    SP-100030
  • HY-131339
    SP-96
    1 Publications Verification

    		 Aurora Kinase Cancer
    SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC50=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI50=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .
    SP-96
  • HY-162091
    Topoisomerase I inhibitor 13

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 13 (Compound G11) is a Topo I inhibitor that inhibits cancer cell proliferation. Topoisomerase I inhibitor 13 significantly inhibits tumor growth in vivo .
    Topoisomerase I inhibitor 13
  • HY-P2979A
    Invertase, candida sp.

    β-D-Fructofuranosidase, candida sp.

    		 Biochemical Assay Reagents Others
    Invertase from Candida sp. is responsible for catalyzing the hydrolysis of sucrose into glucose and fructose and is widely used in the field of carbohydrate processing. Invertase from Candida sp. can be used for enzymatic determination of sucrose concentration as well as for structural analysis of carbohydrates containing β-D-fructofuranosyl residues .
    Invertase, candida sp.
  • HY-156969
    Topoisomerase I inhibitor 11

    		Topoisomerase Btk Cancer
    Topoisomerase I inhibitor 11 is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 11 can bind to BTK .
    Topoisomerase I inhibitor 11
  • HY-P2857A
    Glucoamylase, Rhizopus sp.

    		Others Others
    Glucoamylase, Rhizopus sp. hydrolyzes α-1,4 and α-1,6 glucosidic bonds in starch and similar substrates, and releases β-glucose molecules primarily from the non-reducing end. Glucoamylase, Rhizopus sp. participates in glycogen metabolism, and is related to glycogen storage disease type II. Glucoamylase, Rhizopus sp. converses starch to glucose, which can be used in industrial production of high fructose syrup, alcohol, and other fermented products .
    Glucoamylase, Rhizopus sp.
  • HY-137614
    Sp-GTPαS

    		Biochemical Assay Reagents Others
    Sp-GTPαS is a phosphonothioate analog of GTP. Sp-GTPαS is more metabolically stable than GTP .
    Sp-GTPαS
  • HY-137638A
    Sp-5,6-DCl-cBIMPS sodium

    Sp-5,6-DCI-cBIMPS

    		 PKA Metabolic Disease
    Sp-5,6-DCl-cBIMPS sodium is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS sodium stimulates insulin release. Sp-5,6-DCl-cBIMPS sodium inhibits U-46619 (HY-108566)-induced activation of Rho, Gq and G12/G13 in platelets .
    Sp-5,6-DCl-cBIMPS sodium
  • HY-137632
    Sp-8-Cl-cAMPS

    		PKA Cancer
    Sp-8-Cl-cAMPS is an analog of cAMP (HY-B1511) and a derivative of Sp-8-Cl-cAMP. Sp-8-Cl-cAMPS inhibits the growth of human leukemia cell HL-60 and colon cancer cell LS-174T, with IC50 of 8-100 μM. Sp-8-Cl-cAMPS activates the protein kinases cAKI and cAKII, with Ka of 0.25 and 3.2 μM .
    Sp-8-Cl-cAMPS
  • HY-137639
    Sp-8-Br-cGMPS

    		HCN Channel Neurological Disease
    Sp-8-Br-cGMPS is an analog of cGMP. Sp-8-Br-cGMPS is an agonist for cGMP-gated cation channels (CNG channels), with an EC50 of 106.5 μM. Sp-8-Br-cGMPS induces the currents, without the ability to stabilize the channel open state as a full agonist .
    Sp-8-Br-cGMPS
  • HY-137615
    Sp-GDPαS

    		Biochemical Assay Reagents Others
    Sp-GDPαS is a regulator of GDP-binding proteins. Sp-GDPαS is metabolically more stable than GTP .
    Sp-GDPαS
  • HY-137620
    Sp-dATPαS

    		Biochemical Assay Reagents Others
    Sp-dADPαS is a regulator of ADP-binding proteins. Sp-dADPαS is metabolically more stable than ATP .
    Sp-dATPαS
  • HY-137627
    Sp-ADPαS

    		Biochemical Assay Reagents Others
    Sp-ADPαS is a regulator of ADP-binding proteins. Sp-ADPαS is metabolically more stable than ADP .
    Sp-ADPαS
  • HY-137618
    Sp-dGTPαS

    		Biochemical Assay Reagents Others
    Sp-dGDPαS is a regulator of GDP-binding proteins. Sp-dGDPαS is metabolically more stable than GTP .
    Sp-dGTPαS
  • HY-137619
    Sp-dCTPαS

    		Biochemical Assay Reagents Others
    Sp-dCTPαS is a regulator of CTP-binding proteins. Sp-dCTPαS is metabolically more stable than CTP .
    Sp-dCTPαS
  • HY-137626
    Sp-ATPαS

    		Biochemical Assay Reagents Others
    Sp-ATPαS is a regulator of ATP-binding proteins. Sp-ATPαS is metabolically more stable than ATP .
    Sp-ATPαS
  • HY-P2733A
    Glycerol 3-phosphate Oxidase, Pedio coccus sp.

    GPO, Pedio coccus sp.

    		 Endogenous Metabolite Metabolic Disease
    Glycerol-3-phosphate oxidase, Pedio coccus sp. (GPO, Pedio coccus sp.) is a key intermediate in glycerol metabolism. Glycerol-3-phosphate oxidase is the skeleton of phospholipids in membrane lipids, and also a substrate in the respiratory chain. Glycerol-3-phosphate oxidase produces electrons through oxidation .
    Glycerol 3-phosphate Oxidase, Pedio coccus sp.
  • HY-161794
    SP3N

    		FKBP Cancer
    SP3N is a specific degrader of the prolyl isomerase FKBP12. The alkylamine of SP3N is metabolized to a reactive aldehyde (SP3CHO), which recruits the SCFFBXO22 ligase for FKBP12 degradation. SP3N may be used in research for cancer .
    SP3N
  • HY-125863C
    Glucose-6-phosphate dehydrogenase, Bacillus sp.

    G6PD, Bacillus sp.

    		 Endogenous Metabolite Others
    Glucose-6-phosphate dehydrogenase, Bacillus sp. catalyzes the conversion of glucose-6-phosphate into 6-phosphogluconolactone, and produces reduced nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate in this process. Glucose-6-phosphate dehydrogenase, Bacillus sp. can be used in research about diabetic complications .
    Glucose-6-phosphate dehydrogenase, Bacillus sp.
  • HY-137622
    Sp-cGMPS

    		PKG Cardiovascular Disease
    Sp-cGMPS is an activator of cGMP-dependent protein kinases (PKGs). Sp-cGMPS can be used in cardiovascular disease-related research .
    Sp-cGMPS
  • HY-137635
    Sp-6-Phe-cAMPS

    		PKA Neurological Disease
    Sp-6-Phe-cAMPS is a potent, site-selective and membrane-permeable activator of cAMP-dependent protein kinase. Sp-6-Phe-cAMPS does not activate exchange factors directly activated by cAMP and can therefore be used as an Epac negative control. Sp-6-Phe-cAMPS can be used in the study of neurodegenerative diseases .
    Sp-6-Phe-cAMPS
  • HY-137640
    Sp-8-Br-cAMPS

    		PKA Others
    Sp-8-Br-cAMPS is an analog of cAMP(HY-B1511). Sp-8-Br-cAMPS is an agonist for cAMP, which performs a protein kinase A (PKA) activating activity with EC50 of 360 nM. Sp-8-Br-cAMPS inhibits proliferation of T cells and the haemocyte non-self response in Lepidoptera larve .
    Sp-8-Br-cAMPS
  • HY-161794A
    SP3N hydrochloride

    		FKBP Cancer
    SP3N hydrochloride is a specific degrader of the prolyl isomerase (FKBP12). The alkylamine of SP3N hydrochloride is metabolized to a reactive aldehyde (SP3CHO), which recruits the SCF FBXO22 ligase for FKBP12 degradation. SP3N hydrochloride may be used in research for cancer .
    SP3N hydrochloride
  • HY-137624
    Sp-cAMPS-AM

    		PKA Others
    Sp-cAMPS-AM is an analog of cAMP. Sp-cAMPS-AM acts as the inducer of PKA activation and CREB phosphorylation, through entrance into the cell and release of its parent polar structure Sp-cAMPS .
    Sp-cAMPS-AM
  • HY-12041R
    SP600125 (Standard)

    		JNK Autophagy Apoptosis Ferroptosis Cancer
    SP600125 (Standard) is the analytical standard of SP600125. This product is intended for research and analytical applications. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
    SP600125 (Standard)
  • HY-161795
    SP3CHO

    		Drug Metabolite Cancer
    SP3CHO is an active metabolite generated by the metabolism of SP3N in cell culture by the action of amine oxidase. SP3CHO can induce polyubiquitination of specific proteins by recruiting the SCFFBXO22 E3 ligase complex. SP3CHO can be used in cancer therapy research .
    SP3CHO

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: